{"id":535785,"date":"2026-06-16T07:03:28","date_gmt":"2026-06-16T07:03:28","guid":{"rendered":"https:\/\/www.newjerseyheadlines.com\/news\/story\/535785\/millions-of-americans-still-havent-started-glp1-treatment-heres-why.html"},"modified":"2026-06-16T07:03:28","modified_gmt":"2026-06-16T07:03:28","slug":"millions-of-americans-still-havent-started-glp1-treatment-heres-why","status":"publish","type":"post","link":"http:\/\/www.northcarolinaheadlines.com\/news\/story\/535785\/millions-of-americans-still-havent-started-glp1-treatment-heres-why.html","title":{"rendered":"Millions of Americans Still Haven\u2019t Started GLP-1 Treatment. Here\u2019s Why."},"content":{"rendered":"
\n
\"Millions<\/a><\/div>\n
\n
\u201cMost people who come to Ondra have already spent months researching GLP-1 medications. They\u2019ve compared providers, read studies, watched videos, and talked to friends who are on treatment. They\u2019re not looking for another sales pitch. They\u2019re looking for clarity.\u201d \u2014 Ondra Health<\/div>\n<\/div>\n<\/div>\n
Millions of Americans remain interested in GLP-1 medications but have not yet started treatment. According to Ondra Health, the biggest barrier is no longer awareness or access, but trust. As clinical evidence continues to grow and treatment becomes more accessible, patients are increasingly focused on finding transparent providers, reputable pharmacy partners, and clear information before deciding whether to begin their GLP-1 journey.<\/div>\n

LOS ANGELES, CA –<\/strong> For the last few years, holding off on GLP-1 weight loss treatment was a defensible decision. Prices were high, supply was unpredictable, long-term evidence was still developing, and the online market was crowded with companies that many patients had no way to verify.<\/p>\n

Waiting wasn’t a failure of willpower.<\/p>\n

For a lot of people, it was the responsible call.<\/p>\n

That calculus has changed — and most of the people it changed for haven’t heard the news.<\/p>\n

Today, many of those same people are still waiting. Not because they don’t believe GLP-1 medications work, but because they’re trying to figure out who they can trust.<\/p>\n

That is exactly the patient Ondra Health was built for.<\/p>\n

The Los Angeles-based telehealth platform provides access to compounded semaglutide and tirzepatide through licensed U.S. pharmacy partners, with clinical oversight from licensed healthcare providers and prescriptions issued through Wasef Health, PC.<\/p>\n

“The people we hear from aren’t impulsive. They’re the opposite,” said an Ondra Health spokesperson. “Most have already spent months researching GLP-1 medications. They’ve compared providers, watched videos, read studies, and talked to friends who are on treatment. What they’re looking for now isn’t another advertisement. They’re looking for clarity.”<\/p>\n

The data suggests they’re not alone.<\/p>\n

A 2025 RAND Corporation survey of nearly 9,000 adults found that 14% were interested in taking GLP-1 medications but had not yet started. A KFF poll conducted in late 2025 found that interest rises to 43% among adults who are overweight or obese but are not currently using these medications. And when a January 2026 survey of overweight adults asked what was preventing people from getting started, the answers were consistent: cost concerns, worries about side effects, and uncertainty about whether treatment would actually work.<\/p>\n

Those concerns are understandable.<\/p>\n

They’re also the exact concerns the last several years have increasingly begun to answer.<\/p>\n

What’s Changed?<\/p>\n

The evidence is no longer preliminary.<\/p>\n

Large clinical studies have consistently demonstrated meaningful weight loss outcomes and improvements in important health markers, including blood sugar control, blood pressure, and cardiovascular risk factors. More than three years of widespread use have also generated substantial real-world data, replacing much of the uncertainty that existed when these medications first entered the mainstream conversation.<\/p>\n

The market itself has matured.<\/p>\n

According to Gallup’s National Health and Well-Being Index, GLP-1 use for weight loss more than doubled between early 2024 and late 2025. Access has expanded, awareness has grown, and patients now have more treatment options than ever before.<\/p>\n

Cost barriers have changed as well.<\/p>\n

Historically, brand-name GLP-1 medications often carried monthly costs exceeding $1,000, putting treatment out of reach for many Americans. Today, expanded telehealth access and partnerships with licensed U.S. pharmacies have helped make treatment more accessible for patients whose insurance may not cover obesity treatment.<\/p>\n

J.P. Morgan Research projects approximately 30 million Americans will be using GLP-1 medications by 2030, up from roughly 10 million today.<\/p>\n

Yet despite growing adoption, millions of prospective patients remain stuck in the research phase.<\/p>\n

Built for the Person Who Did Their Homework<\/strong><\/p>\n

According to Ondra Health, many prospective patients are no longer asking whether GLP-1 medications work.<\/p>\n

They’re asking which provider they should trust.<\/p>\n

A simple Google search for semaglutide or tirzepatide can return dozens of telehealth companies, all offering different pricing, pharmacy partners, subscription models, and promises. For patients trying to make an informed healthcare decision, knowing where to start can be overwhelming.<\/p>\n

Ondra Health was designed to simplify that process.<\/p>\n

The platform publishes treatment options, pharmacy partners, and pricing upfront so patients can understand exactly what they’re signing up for before beginning an intake. There are no insurance requirements, no in-person visits, and no hidden membership fees.<\/p>\n

“We believe patients deserve to know exactly what they’re signing up for before they commit,” said the spokesperson. “That means transparent pricing, clear expectations, licensed providers, and reputable pharmacy partners. We built Ondra for people who wanted to feel informed before they felt pressured.”<\/p>\n

The company is also direct about information many patients deserve to know before starting treatment.<\/p>\n

Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved drug products. Ondra Health encourages patients to discuss risks, benefits, and treatment suitability with a licensed healthcare provider before beginning therapy.<\/p>\n

For people who have spent months researching GLP-1 medications, the conversation may no longer be about whether these treatments work.<\/p>\n

It may simply be about finding a provider that makes the decision feel clear.<\/p>\n

To review treatment options, pharmacy partners, transparent pricing, and eligibility requirements, visit ondra.health and see if treatment may be right for you.<\/p>\n

About Ondra Health<\/strong><\/p>\n

Ondra Health is a nationwide telehealth platform offering access to compounded semaglutide and tirzepatide through licensed U.S. pharmacy partners. Clinical prescriptions are issued through Wasef Health, PC. Ondra Health operates across all 50 states with a commitment to transparent pricing, provider-supervised care, and patient education.<\/p>\n

Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved drug products. Individual results vary.<\/em><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Ondra Health<\/a>
Contact Person:<\/strong> Media Relations
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> (310) 571-8224
City:<\/strong> Los Angeles
State:<\/strong> CA
Country:<\/strong> United States
Website:<\/strong> https:\/\/ondra.health<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

\u201cMost people who come to Ondra have already spent months researching GLP-1 medications. They\u2019ve compared providers, read studies, watched videos, and talked to friends who are on treatment. They\u2019re not<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/535785"}],"collection":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/comments?post=535785"}],"version-history":[{"count":0,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/535785\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/media?parent=535785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/categories?post=535785"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/tags?post=535785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}